Pub Date : 2025-11-01DOI: 10.1016/j.canrad.2025.104758
Jordan Eber , Sophie Bockel , Delphine Antoni , Catherine Khamphan , Georges Noël , Clara Le Fèvre
The delineation of organs at risk is fundamental in radiotherapy, ensuring optimal tumour targeting while minimizing toxicity to healthy tissues. Advances in imaging, including MRI-based segmentation and functional imaging, have improved contour precision, while artificial intelligence-assisted autosegmentation enhances efficiency and reproducibility. This article presents updated organs at risk delineation guidelines, incorporating emerging critical structures and refined contouring protocols. Despite technological progress, challenges remain in integrating artificial intelligence-driven tools and functional imaging into routine practice, requiring continued validation and standardization. The future of organs at risk delineation lies in a multidisciplinary approach combining automation, adaptive radiotherapy, and personalized treatment planning to optimize patient safety and long-term outcomes.
{"title":"Delineation of organs at risk in radiotherapy and perspectives","authors":"Jordan Eber , Sophie Bockel , Delphine Antoni , Catherine Khamphan , Georges Noël , Clara Le Fèvre","doi":"10.1016/j.canrad.2025.104758","DOIUrl":"10.1016/j.canrad.2025.104758","url":null,"abstract":"<div><div>The delineation of organs at risk is fundamental in radiotherapy, ensuring optimal tumour targeting while minimizing toxicity to healthy tissues. Advances in imaging, including MRI-based segmentation and functional imaging, have improved contour precision, while artificial intelligence-assisted autosegmentation enhances efficiency and reproducibility. This article presents updated organs at risk delineation guidelines, incorporating emerging critical structures and refined contouring protocols. Despite technological progress, challenges remain in integrating artificial intelligence-driven tools and functional imaging into routine practice, requiring continued validation and standardization. The future of organs at risk delineation lies in a multidisciplinary approach combining automation, adaptive radiotherapy, and personalized treatment planning to optimize patient safety and long-term outcomes.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"29 7","pages":"Article 104758"},"PeriodicalIF":1.4,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145462449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-01DOI: 10.1016/j.canrad.2025.104766
Nicolas Pourel , Laure Parent , Jean-Chirstophe Faivre , Emma Pellen , Fabrice Lorchel , Gianfranco Brusadin
Quality and risk management systems of French radiotherapy centres are relentlessly mutating in order to cope with regulatory changes and new challenges. In April 2021, the Autorité de sûreté nucléaire (ASN, the French nuclear safety authority) strengthened quality assurance requirements by developing change management, professional licensing processes and peer audit. The certification system of the Haute Autorité de santé (HAS, the French high authority for health) is likewise undergoing significant evolutions with each iteration. These developments emphasize the importance of robust organizational frameworks that are regularly assessed and optimized to address risks, with a strong focus on digital challenges.
法国放射治疗中心的质量和风险管理系统不断发生突变，以应对监管变化和新的挑战。2021年4月，法国核安全局（ASN）通过制定变革管理、专业许可流程和同行审计，加强了质量保证要求。法国高级卫生当局（Haute autorit de sant）的认证制度也在每一次迭代中经历着重大的演变。这些发展强调了健全的组织框架的重要性，这些框架需要定期评估和优化以应对风险，并重点关注数字化挑战。
{"title":"Quality and safety in radiation oncology: Innovation and beyond","authors":"Nicolas Pourel , Laure Parent , Jean-Chirstophe Faivre , Emma Pellen , Fabrice Lorchel , Gianfranco Brusadin","doi":"10.1016/j.canrad.2025.104766","DOIUrl":"10.1016/j.canrad.2025.104766","url":null,"abstract":"<div><div>Quality and risk management systems of French radiotherapy centres are relentlessly mutating in order to cope with regulatory changes and new challenges. In April 2021, the Autorité de sûreté nucléaire (ASN, the French nuclear safety authority) strengthened quality assurance requirements by developing change management, professional licensing processes and peer audit. The certification system of the Haute Autorité de santé (HAS, the French high authority for health) is likewise undergoing significant evolutions with each iteration. These developments emphasize the importance of robust organizational frameworks that are regularly assessed and optimized to address risks, with a strong focus on digital challenges.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"29 7","pages":"Article 104766"},"PeriodicalIF":1.4,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145574989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The aim of this article is to present the specifics of clinical research in radiotherapy in France, in order to facilitate the drafting of research protocols. The objectives of research are similar to those of any oncological research: to improve the therapeutic index and, if possible, the results in terms of survival. Phase III trials are still essential, but phase II trials provide interesting information on both the efficacy and tolerability of treatments. The particularities of radiotherapy trials are discussed in terms of inclusion criteria, judgment criteria and therapeutic modalities. The importance of quality control is emphasized. Finally, the difficulties of funding, which is usually academic, are discussed.
{"title":"Specific features of clinical research in radiotherapy in France","authors":"Gilles Créhange , Christophe Hennequin , Benoît Allignet , David Azria , Pierre Blanchard , Igor Latorzeff , Véronique Vendrely , Catherine Dejean , Laure Parent , Régis Ferrand , Yoann Pointreau","doi":"10.1016/j.canrad.2025.104768","DOIUrl":"10.1016/j.canrad.2025.104768","url":null,"abstract":"<div><div>The aim of this article is to present the specifics of clinical research in radiotherapy in France, in order to facilitate the drafting of research protocols. The objectives of research are similar to those of any oncological research: to improve the therapeutic index and, if possible, the results in terms of survival. Phase III trials are still essential, but phase II trials provide interesting information on both the efficacy and tolerability of treatments. The particularities of radiotherapy trials are discussed in terms of inclusion criteria, judgment criteria and therapeutic modalities. The importance of quality control is emphasized. Finally, the difficulties of funding, which is usually academic, are discussed.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"29 7","pages":"Article 104768"},"PeriodicalIF":1.4,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145662741","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-01DOI: 10.1016/j.canrad.2025.104780
Yuedan Zhou , Alexandre Escande , Arnaud Beddok , Cyrus Chargari , Marie-Pierre Sunyach , Myriam Ayadi , Jonathan Khalifa , Delphine Antoni , Kim Cao , David Pasquier , Jean-Michel Hannoun-Lévi , Martin Langé , Jean-Christophe Faivre , Sébastien Thureau , Stéphane Supiot
The process of reirradiation in oncology presents a distinctive set of challenges, wherein clinical decision-making is predicated on a delicate balancing act between the efficacy of the treatment and the risk of severe toxicity. Despite the paucity of randomised and prospective data, there is an increasing number of data encouraging its consideration for patients with local or metastatic recurrence. While awaiting dedicated guidance from international scientific societies, this publication is based on multicentre reflections of the “Recommendations Commission” of the Société française de radiothérapie oncologique (the French society for radiation oncology). It addresses key questions related to reirradiation, with a particular focus on lung, breast and bone tumours.
肿瘤学中的再照射过程呈现出一系列独特的挑战，其中临床决策是基于治疗效果和严重毒性风险之间的微妙平衡。尽管缺乏随机和前瞻性数据，但越来越多的数据鼓励将其用于局部或转移性复发患者。在等待国际科学学会的专门指导的同时，本出版物是基于法国放射肿瘤学学会（societosterfranaise de radithaprapie oncologique）“建议委员会”的多中心反思。它解决了与再照射有关的关键问题，特别侧重于肺、乳腺和骨肿瘤。
{"title":"Reirradiation of lung, breast and bone tumours, suggestions from the Recommendations Commission of the Société française de radiothérapie oncologique","authors":"Yuedan Zhou , Alexandre Escande , Arnaud Beddok , Cyrus Chargari , Marie-Pierre Sunyach , Myriam Ayadi , Jonathan Khalifa , Delphine Antoni , Kim Cao , David Pasquier , Jean-Michel Hannoun-Lévi , Martin Langé , Jean-Christophe Faivre , Sébastien Thureau , Stéphane Supiot","doi":"10.1016/j.canrad.2025.104780","DOIUrl":"10.1016/j.canrad.2025.104780","url":null,"abstract":"<div><div>The process of reirradiation in oncology presents a distinctive set of challenges, wherein clinical decision-making is predicated on a delicate balancing act between the efficacy of the treatment and the risk of severe toxicity. Despite the paucity of randomised and prospective data, there is an increasing number of data encouraging its consideration for patients with local or metastatic recurrence. While awaiting dedicated guidance from international scientific societies, this publication is based on multicentre reflections of the “Recommendations Commission” of the Société française de radiothérapie oncologique (the French society for radiation oncology). It addresses key questions related to reirradiation, with a particular focus on lung, breast and bone tumours.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"29 7","pages":"Article 104780"},"PeriodicalIF":1.4,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145614827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-01DOI: 10.1016/j.canrad.2025.104775
Kévin Quintin , Stéphanie Josset , Igor Latorzeff , Yoann Pointreau , Julian Biau , Delphine Antoni , Emmanuel Mesny
We present the updated recommendations of the Société française de radiothérapie oncologique (the French society for radiation oncology) on benign intracranial tumours. Most of them are meningiomas, vestibular schwannomas, pituitary adenomas, craniopharyngiomas, and glomus tumours. Some grow very slowly, and can be observed without specific treatment, especially if they are asymptomatic. Symptomatic or growing tumours are treated by surgery, which is the reference treatment. When surgery is not possible, due to the location of the lesion, or general conditions, radiotherapy can be applied, as it is if there is a postoperative growing residual tumour, or a local relapse. Indications must be discussed at a multidisciplinary panel, with precise evaluation of the benefit and risks of the treatments. The techniques to be used are the most modern ones, as multimodal imaging and image-guided radiation therapy. Stereotactic treatments, using fractionated or single (radiosurgery) doses depending on the size or the location of the tumours, are commonly realized, to avoid as much a possible the occurrence of late side effects.
{"title":"Radiotherapy of benign intracranial tumours: 2025 update","authors":"Kévin Quintin , Stéphanie Josset , Igor Latorzeff , Yoann Pointreau , Julian Biau , Delphine Antoni , Emmanuel Mesny","doi":"10.1016/j.canrad.2025.104775","DOIUrl":"10.1016/j.canrad.2025.104775","url":null,"abstract":"<div><div>We present the updated recommendations of the Société française de radiothérapie oncologique (the French society for radiation oncology) on benign intracranial tumours. Most of them are meningiomas, vestibular schwannomas, pituitary adenomas, craniopharyngiomas, and glomus tumours. Some grow very slowly, and can be observed without specific treatment, especially if they are asymptomatic. Symptomatic or growing tumours are treated by surgery, which is the reference treatment. When surgery is not possible, due to the location of the lesion, or general conditions, radiotherapy can be applied, as it is if there is a postoperative growing residual tumour, or a local relapse. Indications must be discussed at a multidisciplinary panel, with precise evaluation of the benefit and risks of the treatments. The techniques to be used are the most modern ones, as multimodal imaging and image-guided radiation therapy. Stereotactic treatments, using fractionated or single (radiosurgery) doses depending on the size or the location of the tumours, are commonly realized, to avoid as much a possible the occurrence of late side effects.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"29 7","pages":"Article 104775"},"PeriodicalIF":1.4,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145575967","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-01DOI: 10.1016/j.canrad.2025.104728
Audrey Larnaudie , Florent Carsuzaa , Nolwenn Delaby , Valérie Costes-Martineau , Mélanie Doré , Charles Dupin , France Nguyen , Pierre Blanchard , Yoann Pointreau , Ludovic de Gabory , Juliette Thariat
Sinonasal cancers, including tumours of the nasal cavity, ethmoid, maxillary, sphenoid, and frontal sinuses, account for 3 to 5 % of head and neck malignancies. While the majority are carcinomas, other histologic types such as mucosal melanomas, sarcomas, and lymphomas may also occur. These tumours often present with non-specific symptoms and exhibit a heterogeneous prognosis. The Réseau d’expertise français des cancers ORL rares (the French expert network for rare head and neck cancers), accredited by the Institut national du cancer (the French national cancer institute), is responsible for maintaining the national registry and coordinating rare cancer multidisciplinary tumour boards at both regional and national levels. These boards incorporate expert pathological review through Refcorpath (when appropriate) and provide therapeutic recommendations. Due to the distinct characteristics of these tumours, including histologic subtype, grade, risk of nodal involvement, and surgical approach, careful consideration must be given to target volume delineation during locoregional radiotherapy. This article provides an updated overview of the Société française de radiothérapie oncologique (the French society for radiation oncology) recommendations concerning the indications for radiotherapy in sinonasal cancers. It covers key aspects such as treatment planning, techniques, dose and volume specifications, and post-treatment follow-up.
{"title":"Radiotherapy of sinonasal cancers: 2025 update","authors":"Audrey Larnaudie , Florent Carsuzaa , Nolwenn Delaby , Valérie Costes-Martineau , Mélanie Doré , Charles Dupin , France Nguyen , Pierre Blanchard , Yoann Pointreau , Ludovic de Gabory , Juliette Thariat","doi":"10.1016/j.canrad.2025.104728","DOIUrl":"10.1016/j.canrad.2025.104728","url":null,"abstract":"<div><div>Sinonasal cancers, including tumours of the nasal cavity, ethmoid, maxillary, sphenoid, and frontal sinuses, account for 3 to 5 % of head and neck malignancies. While the majority are carcinomas, other histologic types such as mucosal melanomas, sarcomas, and lymphomas may also occur. These tumours often present with non-specific symptoms and exhibit a heterogeneous prognosis. The Réseau d’expertise français des cancers ORL rares (the French expert network for rare head and neck cancers), accredited by the Institut national du cancer (the French national cancer institute), is responsible for maintaining the national registry and coordinating rare cancer multidisciplinary tumour boards at both regional and national levels. These boards incorporate expert pathological review through Refcorpath (when appropriate) and provide therapeutic recommendations. Due to the distinct characteristics of these tumours, including histologic subtype, grade, risk of nodal involvement, and surgical approach, careful consideration must be given to target volume delineation during locoregional radiotherapy. This article provides an updated overview of the Société française de radiothérapie oncologique (the French society for radiation oncology) recommendations concerning the indications for radiotherapy in sinonasal cancers. It covers key aspects such as treatment planning, techniques, dose and volume specifications, and post-treatment follow-up.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"29 7","pages":"Article 104728"},"PeriodicalIF":1.4,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145575949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-01DOI: 10.1016/j.canrad.2025.104773
Quentin Duhoux , Vincent Marchesi , Fabrice Lorchel , David Azria , Ulrike Schick , Isabelle Barillot
The purpose of this article is to describe the external irradiation process and updated recommendations of the Société française de radiothérapie oncologique for patient follow-up.
{"title":"External irradiation treatment process: 2025 update","authors":"Quentin Duhoux , Vincent Marchesi , Fabrice Lorchel , David Azria , Ulrike Schick , Isabelle Barillot","doi":"10.1016/j.canrad.2025.104773","DOIUrl":"10.1016/j.canrad.2025.104773","url":null,"abstract":"<div><div>The purpose of this article is to describe the external irradiation process and updated recommendations of the Société française de radiothérapie oncologique for patient follow-up.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"29 7","pages":"Article 104773"},"PeriodicalIF":1.4,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145614825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-01DOI: 10.1016/j.canrad.2025.104763
Luc Simon , Benoît Allignet , Thomas Leroy , Myriam Ayadi , Julien Darréon
Respiratory motion significantly impacts the precision of radiotherapy for thoracic and abdominal tumours. This article updates a prior review on respiratory management in radiotherapy, focusing on emerging technologies and clinical implementations. Respiratory-induced tumour motion, ranging from 1 to 3 cm during free breathing, introduces uncertainties in imaging, target delineation, and dose delivery. To mitigate these, various respiratory motion management strategies have been developed, encompassing techniques such as deep inspiration breath-hold, internal target volume (ITV), mid-position approaches, gating, and real-time tracking. Recent advancements, including intelligent four-dimensional computed tomography, magnetic resonance imaging-guided linear accelerators, and surface-guided radiotherapy, enhance imaging quality and treatment precision. Dosimetric studies show these technologies reduce radiation exposure to healthy tissues, particularly in complex scenarios like left-sided breast cancer or locally advanced non-small cell lung cancer. Despite clear dosimetric benefits, clinical outcome comparisons among respiratory motion management techniques remain limited, necessitating further investigation. Successful respiratory motion management integration into clinical workflows requires interdisciplinary collaboration, patient-specific strategy selection, and systematic quality assurance. Emerging methods, such as mechanically assisted non-invasive ventilation and advanced magnetic resonance imaging-based gating, further refine motion management. Quality assurance protocols, including end-to-end tests using dynamic phantoms, ensure the reproducibility and accuracy of respiratory motion management strategies. This review highlights the importance of adapting respiratory motion management techniques to patient-specific needs and evolving technologies. By addressing respiratory motion, radiotherapy can achieve improved tumour targeting and reduced toxicity, paving the way for more effective and patient-centred cancer treatments.
{"title":"Respiratory motion management for external radiotherapy: 2025 update","authors":"Luc Simon , Benoît Allignet , Thomas Leroy , Myriam Ayadi , Julien Darréon","doi":"10.1016/j.canrad.2025.104763","DOIUrl":"10.1016/j.canrad.2025.104763","url":null,"abstract":"<div><div>Respiratory motion significantly impacts the precision of radiotherapy for thoracic and abdominal tumours. This article updates a prior review on respiratory management in radiotherapy, focusing on emerging technologies and clinical implementations. Respiratory-induced tumour motion, ranging from 1 to 3<!--> <!-->cm during free breathing, introduces uncertainties in imaging, target delineation, and dose delivery. To mitigate these, various respiratory motion management strategies have been developed, encompassing techniques such as deep inspiration breath-hold, internal target volume (ITV), mid-position approaches, gating, and real-time tracking. Recent advancements, including intelligent four-dimensional computed tomography, magnetic resonance imaging-guided linear accelerators, and surface-guided radiotherapy, enhance imaging quality and treatment precision. Dosimetric studies show these technologies reduce radiation exposure to healthy tissues, particularly in complex scenarios like left-sided breast cancer or locally advanced non-small cell lung cancer. Despite clear dosimetric benefits, clinical outcome comparisons among respiratory motion management techniques remain limited, necessitating further investigation. Successful respiratory motion management integration into clinical workflows requires interdisciplinary collaboration, patient-specific strategy selection, and systematic quality assurance. Emerging methods, such as mechanically assisted non-invasive ventilation and advanced magnetic resonance imaging-based gating, further refine motion management. Quality assurance protocols, including end-to-end tests using dynamic phantoms, ensure the reproducibility and accuracy of respiratory motion management strategies. This review highlights the importance of adapting respiratory motion management techniques to patient-specific needs and evolving technologies. By addressing respiratory motion, radiotherapy can achieve improved tumour targeting and reduced toxicity, paving the way for more effective and patient-centred cancer treatments.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"29 7","pages":"Article 104763"},"PeriodicalIF":1.4,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145462453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Salivary gland tumours are relatively common among rare tumors and encompass both benign (mostly) and malignant entities (not to be initially misdiagnosed). Early diagnosis and appropriate management are crucial determinants of prognosis. The treatment of malignant tumours is guided by their wide histological diversity and grading, each requiring specific therapeutic strategies. Surgical resection remains the standard of care, with ipsilateral neck dissection recommended for intermediate- or high-grade malignancies. Postoperative radiotherapy is indicated for high-grade tumours, pT3 or higher stages, positive surgical margins, or lymph node involvement. In cases with extensive perineural invasion, particularly in adenoid cystic carcinoma, inclusion of the affected nerve pathways in the radiation field should be considered. Benign salivary gland tumours generally do not require radiotherapy, though its use may be discussed in selected cases of multirecurrent pleomorphic adenoma, where management remains controversial. This article summarizes and updates the recommendations of the Société française de radiothérapie oncologique (the French society for radiation oncology) regarding the indications and technical aspects of radiotherapy for salivary gland tumours, with emphasis on fractionation schedules, target volume delineation, and organ-at-risk sparing.
{"title":"Radiotherapy of salivary gland tumours: 2025 update","authors":"Audrey Larnaudie , Valérie Costes-Martineau , Nolwenn Delaby , Mélanie Doré , Yoann Pointreau , Sébastien Vergez , Juliette Thariat","doi":"10.1016/j.canrad.2025.104772","DOIUrl":"10.1016/j.canrad.2025.104772","url":null,"abstract":"<div><div>Salivary gland tumours are relatively common among rare tumors and encompass both benign (mostly) and malignant entities (not to be initially misdiagnosed). Early diagnosis and appropriate management are crucial determinants of prognosis. The treatment of malignant tumours is guided by their wide histological diversity and grading, each requiring specific therapeutic strategies. Surgical resection remains the standard of care, with ipsilateral neck dissection recommended for intermediate- or high-grade malignancies. Postoperative radiotherapy is indicated for high-grade tumours, pT3 or higher stages, positive surgical margins, or lymph node involvement. In cases with extensive perineural invasion, particularly in adenoid cystic carcinoma, inclusion of the affected nerve pathways in the radiation field should be considered. Benign salivary gland tumours generally do not require radiotherapy, though its use may be discussed in selected cases of multirecurrent pleomorphic adenoma, where management remains controversial. This article summarizes and updates the recommendations of the Société française de radiothérapie oncologique (the French society for radiation oncology) regarding the indications and technical aspects of radiotherapy for salivary gland tumours, with emphasis on fractionation schedules, target volume delineation, and organ-at-risk sparing.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"29 7","pages":"Article 104772"},"PeriodicalIF":1.4,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145575965","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Oesophageal and gastric cancers are associated with a poor prognosis, as diagnosis is often delayed in fragile, comorbid patients. Radiotherapy plays a pivotal role in the treatment of oesophageal cancer. It is indicated in combination with chemotherapy for squamous cell carcinoma and for locally advanced, inoperable adenocarcinoma (i.e., non-operable patients or unresectable tumours). Additionally, chemoradiotherapy may be proposed in the preoperative setting for squamous cell carcinoma or for adenocarcinomas when peri-operative chemotherapy is not feasible. For resectable gastric adenocarcinomas, the indications for radiotherapy are limited. However, radiotherapy may be useful in a palliative setting in case of dysphagia or bleeding. Recent technological advances, such as image-guided radiotherapy and conformal intensity-modulated radiotherapy, have considerably improved the tolerance of treatments, particularly in curative approaches. These innovations optimize target volume coverage while limiting toxicity on adjacent organs at risk, notably the heart and lungs. We present here the updated guidelines of the Société française de radiothérapie oncologique (SFRO) regarding the indications and technical modalities of radiotherapy for oesophageal and gastric cancers.
{"title":"Radiotherapy for cancers of the oesophagus, gastroesophageal junction, and stomach","authors":"Corentin Pasquier , Gilles Créhange , Véronique Vendrely , Igor Bessières , Laurent Quéro , Florence Huguet , Anouchka Modesto","doi":"10.1016/j.canrad.2025.104759","DOIUrl":"10.1016/j.canrad.2025.104759","url":null,"abstract":"<div><div>Oesophageal and gastric cancers are associated with a poor prognosis, as diagnosis is often delayed in fragile, comorbid patients. Radiotherapy plays a pivotal role in the treatment of oesophageal cancer. It is indicated in combination with chemotherapy for squamous cell carcinoma and for locally advanced, inoperable adenocarcinoma (i.e., non-operable patients or unresectable tumours). Additionally, chemoradiotherapy may be proposed in the preoperative setting for squamous cell carcinoma or for adenocarcinomas when peri-operative chemotherapy is not feasible. For resectable gastric adenocarcinomas, the indications for radiotherapy are limited. However, radiotherapy may be useful in a palliative setting in case of dysphagia or bleeding. Recent technological advances, such as image-guided radiotherapy and conformal intensity-modulated radiotherapy, have considerably improved the tolerance of treatments, particularly in curative approaches. These innovations optimize target volume coverage while limiting toxicity on adjacent organs at risk, notably the heart and lungs. We present here the updated guidelines of the Société française de radiothérapie oncologique (SFRO) regarding the indications and technical modalities of radiotherapy for oesophageal and gastric cancers.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"29 7","pages":"Article 104759"},"PeriodicalIF":1.4,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145462450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号